A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
Clinical trial NCT06259552 · RECRUITING
Trial details
- NCT number
- NCT06259552
- Sponsor
- SparX Biotech(Jiangsu) Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-20
- Primary completion
- 2027-09-01
- Enrollment
- 232
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.